The Biosimilars Resource Centre is an educational portal that helps healthcare professionals develop their knowledge of biosimilars through e-Learning modules and curated peer-reviewed content. By providing three UEMS-EACCME-accredited e-Learning modules and the latest research, hand-picked by editors, the Resource Centre aims to disseminate knowledge on biosimilars for rheumatologists, gastroenterologists and dermatologists.
Modules 1, 2 and 3 are available now. To keep up-to-date with the latest additions to the Resource Centre, you can sign up for our E-Alerts.
Access the courses here
About the courses
With three UEMS-EACCME-accredited e-Learning modules, learners can dive into the topic of biosimilars, increasing their understanding and knowledge for improved practical applications and outcomes.
Each e-Learning module takes 45 minutes to complete and is worth 1 UEMS-EACCME credit. The modules are accompanied by three freely downloadable slide decks that learners can share with peers (non-CME accredited). Up to five new peer-reviewed articles are added every month to complement the content.
Three expert guest editors act as independent expert reviewers, in line with UEMS guidelines, and curate the content of the three e-Learning modules.
A biosimilar is a biologic medicinal drug that is a copy of a drug made by another company. Biosimilars can be manufactured once the original drug’s patent has expired, and must go through approval processes that involve citing the original drug.
Unlike generics, biosimilars are not carbon copies of their originators. Because they are made of biological molecules, they are more complex, and typically 10 to 1000 times the size of the small molecules that constitute generic drugs, making it almost impossible to create an exact copy.
Biosimilars can cut the cost of treatments in a similar way to generics; this makes them economically as well as clinically important for healthcare systems and professionals. And this is reflected in the figures – the biosimilars market is set to soar to over $6 billion in the next five years.
Despite this, familiarity with and knowledge of biosimilars is generally low in the medical community, with 25% of doctors never having heard of them, according to one survey.
Lutz Heinemann, PhD, Hootan Khatami, MD, Ross McKinnon, PhD and Philip Home, MA, DPhil, DM, FRCPDiabetes Technology & TherapeuticsTopic: Usage & Applications
L. Heinemann, P. D. Home, M. HompeschDiabetes, Obesity and MetabolismTopic: Regulatory Affairs
Paola Minghetti, Paolo Rocco, Francesco Cilurzo, Lucia Del Vecchio, Francesco Locatelli
Drug Discovery Today, Volume 17, Issue 1-2, January 2012, Pages 63 - 70Topic: Regulatory Affairs
Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
Gilberto Castañeda-Hernández, Zoltan Szekanecz, Eduardo Mysler, Valderilio F. Azevedo, Renato Guzman, Miguel Gutierrez, Wilfredo Rodríguez, Dmitry Karateev
Joint Bone Spine, Volume 81, Issue 6, December 2014, Pages 471 - 477
Case studies on clinical evaluation of biosimilar monoclonal antibody: Scientific considerations for regulatory approval
Alex Kudrin, Ivana Knezevic, Jeewon Joung, Hye-Na Kang
Biologicals, Volume 43, Issue 1, January 2015, Pages 1 - 10
Lynne A. Bui, Susan Hurst, Gregory L. Finch, Beverly Ingram, Ira A. Jacobs, Carol F. Kirchhoff, Chee-Keng Ng, Anne M. Ryan
Drug Discovery Today, May 2015, Pages 3 - 15
Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States
Islah Ahmed MD, Ben Kaspar MS, Uma Sharma PhD
Clinical Therapeutics, Volume 34, Issue 2, February 2012, Pages 400 - 419